Literature DB >> 9881638

Mechanisms by which Hange-shashin-to reduces prostaglandin E2 levels.

Y Kase1, K Saitoh, A Ishige, Y Komatsu.   

Abstract

To determine the mechanisms by which Hange-shashin-to (TJ-14) reduces prostaglandin E2 (PGE2) levels, the effects on blood corticosterone levels were examined in vivo and the effects on cyclooxygenase (COX) activity in vitro assessed. TJ-14, orally administered to rats at dose levels between 125 and 1000 mg/kg, caused a dose-dependent increase in blood corticosterone levels. We also showed that Glycyrrhizae Radix and Ginseng Radix, constituents of TJ-14, are involved in the increase in blood corticosterone. The activity of COX-1 was not inhibited by TJ-14 even at a dose of 1000 microg/ml, while COX-2 was inhibited at dose levels between 10 and 1000 microg/ml. The constituents Scutellariae Radix, Glycyrrhizae Radix and Coptidis Rhizoma were believed to be involved in COX-2 inhibition. These results suggest that the effect of TJ-14 in decreasing PGE2 is partially mediated by corticosterone and inhibition of COX-2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881638     DOI: 10.1248/bpb.21.1277

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  14 in total

1.  Effect of Hangeshashinto on calprotectin expression in human oral epithelial cells.

Authors:  Yuka Hiroshima; Mika Bando; Yuji Inagaki; Reiko Kido; Masatoshi Kataoka; Toshihiko Nagata; Jun-Ichi Kido
Journal:  Odontology       Date:  2015-02-04       Impact factor: 2.634

2.  Modulation of PPARγ and TNFα by emu oil and glycyrrhizin in ulcerative colitis.

Authors:  Sri Nandhini Sethuraman; Selvasubramanian Swaminathan; Shinu B Nelson; Preetha S Palaninathan; Tirumurugaan K Gopalan; Pandiyan Velayudham
Journal:  Inflammopharmacology       Date:  2015-01-06       Impact factor: 4.473

3.  Hangeshashinto (TJ-14) prevents radiation-induced mucositis by suppressing cyclooxygenase-2 expression and chemotaxis of inflammatory cells.

Authors:  D Kamide; T Yamashita; K Araki; M Tomifuji; A Shiotani
Journal:  Clin Transl Oncol       Date:  2017-05-17       Impact factor: 3.405

4.  A traditional Japanese medicine--Hangeshashinto (TJ-14)--alleviates chemoradiation-induced mucositis and improves rates of treatment completion.

Authors:  Taku Yamashita; Koji Araki; Masayuki Tomifuji; Daisuke Kamide; Yuya Tanaka; Akihiro Shiotani
Journal:  Support Care Cancer       Date:  2014-06-19       Impact factor: 3.603

5.  Herbal medicines for the treatment of cancer chemotherapy-induced side effects.

Authors:  Shunsuke Ohnishi; Hiroshi Takeda
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

6.  Studies on Shokyo, Kanzo, and Keihi in Kakkonto Medicine on Prostaglandin E2 Production in Lipopolysaccharide-Treated Human Gingival Fibroblasts.

Authors:  Toshiaki Ara; Norio Sogawa
Journal:  Int Sch Res Notices       Date:  2016-10-13

7.  Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer.

Authors:  Masao Ichiki; Hiroshi Wataya; Kazuhiko Yamada; Nobuko Tsuruta; Hiroaki Takeoka; Yusuke Okayama; Jun Sasaki; Tomoaki Hoshino
Journal:  Onco Targets Ther       Date:  2017-10-24       Impact factor: 4.147

8.  CPT-11-Induced Delayed Diarrhea Develops via Reduced Aquaporin-3 Expression in the Colon.

Authors:  Risako Kon; Yuika Tsubota; Moe Minami; Saki Kato; Yukari Matsunaga; Hiroshi Kimura; Yuta Murakami; Tetsuya Fujikawa; Ryoya Sakurai; Rei Tomimoto; Yoshiaki Machida; Nobutomo Ikarashi; Kiyoshi Sugiyama
Journal:  Int J Mol Sci       Date:  2018-01-06       Impact factor: 5.923

Review 9.  Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application.

Authors:  Kazunari Tominaga; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2013-03-16       Impact factor: 7.527

10.  Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis.

Authors:  Toru Aoyama; Kazuhiro Nishikawa; Nobuhiro Takiguchi; Kazuaki Tanabe; Motohiro Imano; Ryoji Fukushima; Junichi Sakamoto; Mari S Oba; Satoshi Morita; Toru Kono; Akira Tsuburaya
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-21       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.